Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology

Maya Suzuki, Kevin J. Curran, Nai Kong V. Cheung

研究成果: Contribution to journalReview article査読

9 被引用数 (Scopus)

抄録

Cancer immunotherapy using antigen-specific T cells has broad therapeutic potential. Chimeric antigen receptors and bispecific antibodies can redirect T cells to kill tumors without human leukocyte antigens (HLA) restriction. Key determinants of clinical potential include the choice of target antigen, antibody specificity, antibody affinity, tumor accessibility, T cell persistence, and tumor immune evasion. For pediatric cancers, additional constraints include their propensity for bulky metastatic disease and the concern for late toxicities from treatment. Nonetheless, the recent preclinical and clinical developments of these T cell based therapies are highly encouraging.

本文言語英語
ページ(範囲)1326-1336
ページ数11
ジャーナルPediatric Blood and Cancer
62
8
DOI
出版ステータス出版済み - 8 1 2015
外部発表はい

All Science Journal Classification (ASJC) codes

  • 小児科学、周産期医学および子どもの健康
  • 血液学
  • 腫瘍学

フィンガープリント

「Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル